When a patient is found to have a thyroid nodule, doctors must decide if it is likely to be cancerous. This decision often determines whether a patient needs surgery. A large review of 127 studies looked at how molecular testing, or MT, helps guide these decisions for patients in both Western and Asian regions.
In Western countries, the study found that patients who did not have molecular testing had a 66.8% surgery rate, while those who did have testing had a 42.5% rate. In Asian countries, the surgery rate dropped from 53.9% without testing to 37.4% with testing. While the numbers are different, the trend shows that molecular testing helps reduce the number of surgeries performed in both regions.
However, the role of these tests varies by location. In the West, the test is often used to rule out the need for surgery. In Asia, it is used more to confirm the risk level of the nodule. Because the study shows different risk levels and surgical needs across these regions, patients should talk to their doctors about how these tests apply to their specific situation.
